65 results about "Scavenger receptor" patented technology

A method of reducing an inflammatory response in a subject is provided. The method comprising providing to a subject in need thereof a therapeutically effective amount of an agent capable of reducing activity and/or expression of a scavenger receptor or of an effector thereof, thereby reducing the inflammatory response in the subject.

The invention relates to preparation and application of a gene and chemotherapeutic drug co-delivery anti-tumor nanoparticle of a target SR-BI (Scavenger Receptor-BI). The nanoparticle is a recombinant high density lipoprotein drug-loaded nanoparticle, comprises phospholipid, cholesterol, cholesteryl ester, apolipoprotein, cation lipid, a chemotherapeutic drug, a gene drug and the like, and is prepared by a film dispersion method. The invention aims at preparing the bionic tumor target drug-loaded nanoparticle, the preparation condition is mild, and the cost is low. The invention further provides the application of the gene and chemotherapeutic drug co-delivery anti-tumor nanoparticle. The gene and chemotherapeutic drug co-delivery anti-tumor nanoparticle has the advantages of spherical structure, good encapsulation efficiency, low cytotoxicity, good targeting, high safety, significant in-vitro anti-tumor effect and the like.

As illustrated herein, cholesterol is oxidized when it is present in atherosclerotic plaques. This reaction generates cholesterol oxidation or ozonation products that can act as chemotactic attractants of macrophages, can promote differentiation of monocytes into macrophages and can increase expression of E-selectin and Class A scavenger receptor (SR-A). The present application is directed to methods of using such cholesterol ozonoation products to identify agents that can be used to treat atherosclerosis and other inflammatory artery diseases.

The invention belongs to the technical field of aquatic breeding, and particularly relates to a growth-related molecular marker in a C-type scavenger receptor gene (LvSRC) of Litopenaeusvannamei and application thereof to genetic breeding of the Litopenaeusvannamei. A batch of markers related to shrimp growth traits are positioned in the genomic level through genome-wide association analysis, a single nucleotide polymorphism (SNP) marker (LvSRC-211-G/T) positioned in a coding region of the LvSRC gene is further screened through gene annotation and by a candidate gene association analysis method, and the genotype of the marker is significantly correlated to the shrimp growth traits (P is smaller than 10<-6>). The marker is positioned at a 211bp position on the LvSRC gene and belongs to G/Ttype mutation, and the GT genotype of the marker is a distinct growth-dominant genotype. The marker provided by the invention can be used as the shrimp breeding molecular marker for assisting in genetic selection of the shrimp growth traits.

The invention relates to a group of 1-substituted-1, 8-naphthyridine formamide derivatives, and a preparation method and an application thereof. The biological experimental studies show that the tested compounds in the derivatives remarkably inhibit the apical sodium-dependent bile acid transporter (ASBT) at the cellular level, and have increased effect on the expression of ABCA1 (ATP-binding cassette transporter A1) and SR-BI (scavenger receptor type B class I), thereby being expected to be developed to become a clinically effective medicament for treating associated cardiovascular diseases.

An animal model has been developed where the animals can survive myocardial infarctions caused by diet-induced coronary atherosclerosis, and live with chronic heart failure. This animal model is a result of reduced activity of scavenger receptor class BI (SR-BI) and ApoE and the inducible activity of the Mx1-Cre gene. In a preferred embodiment, the model is a result of crossbreeding two transgenic mouse lines: a knockout of SR-BI (SRBI^−/−) and an impaired ApoE expressor (Apoe^h/h) to generate a strain referred to as Apoe^h/hSRB1^−/− mice, which is then crossbred to mice that carry the inducible Mx1-Cre transgene. The Apoe^h/hSRB1^−/− mouse model is genetically modified, enabling the offspring to rapidly and permanently lower their high blood cholesterol levels caused by dietary challenge. The ability to rapidly and permanently lower blood cholesterol levels in these mice stops and may cause the regression of occlusive coronary atherosclerosis restoring blood flow to the heart, allowing the mice to survive from myocardial infarction and live with chronic heart failure.

The invention discloses a multi-mode ferritin nanometer contrast agent based on ferritin and a preparation method thereof. Horse spleen ferritin with the targeted performance on macrophage surface scavenger receptors 5 is used as a biological nanometer template (shell); prussian blue nanometer particles are used as cores to realize MRI and photoacoustic imaging; next, fluorescent dye IR-782 is coupled to be used as a fluorescence probe part; the multi-mode ferritin nanometer contrast agent of a shell core structure is prepared. The multi-mode ferritin nanometer contrast agent combines the photoacoustic imaging, fluorescence imaging and MRI trimodal imaging, can be used for sentinel lymph node photoacoustic/MRI/fluorescence trimodal radiography before breast cancer, can also be used for performing blue dyeing on the sentinel lymph node before breast cancer by using the dyeing effect of the prussian blue, realizes the comprehensive and precise diagnosis of the breast cancer lymphatic metastasis, and promotes the development of clinic medicine and image diagnostics.

Provided are DNA-coated nanoparticles (DNA-NPS), superparamagnetic nanoparticles (DNA-SPNs), and superparamagnetic iron oxide nanoparticles (DNA-SPIONs) as efficient imaging agents for targeting and imaging atherosclerotic lesions and treating atherosclerotic disease. The DNA-NS, DNA-SPNs, and DNA-SPIONs can enter macrophage cells via the Class A scavenger receptor (SR-A)-mediated pathways and can be used to specifically target atheroscleortic plaques.

The invention provides a large yellow croaker scavenger receptor SCARA3 gene and application thereof, and belongs to the technical field of genetic engineering. The complete ORF of the large yellow croaker scavenger receptor SCARA3 gene includes 1938 basic groups, and the nucleotide sequence is shown as SEQ ID NO:1; under the infection of vibrio harveyi, the expression quantity of the gene is up-regulated, and the gene can be applied to detecting the vibrio harveyi resistance of large yellow croaker parents and/or breeding the vibrio-harveyi-resistant fine species and especially can be appliedto detecting the vibrio harveyi resistance of the large yellow croaker parents and/or breeding the vibrio-harveyi-resistant fine species. Recombinant expression protein of large yellow croaker scavenger receptor protein coded by the large yellow croaker scavenger receptor SCARA3 gene has remarkable vibrio-harveyi-resistant activity and can be used for preparing vibrio-harveyi-resistant biologicalproducts, and a gene sequence and method are provided for the research on the large yellow croaker vibrio-harveyi-resistant mechanism and the development of vibrio-harveyi-resistant feed additives.

The present invention relates to a cell culture system to provide a tool for assessing the potential of a patient's serum for preventing the accumulation of cholesterol in arteries (i.e. serum efflux potential) that leads to atherosclerosis and to screen new drug compositions being developed to reduce the accumulation of cholesterol or enhance the clearance of cholesterol from the vessel wall. The present invention combines two individual assays, which are two different cholesterol assays: an assay measuring scavenger receptor class B type I (SR-BI)-mediated cholesterol efflux and an assay measuring ATP binding cassette protein 1 (ABCA1)-mediated cholesterol efflux, and uses them in parallel to test human and animal sera for their potential to stimulate efflux, as mediated by either of the two receptors described above.

A scavenger receptor A expression down-regulator and a drug for preventing or treating arteriosclerosis which contain, as the active ingredient, a C-terminal globular domain of adiponectin, adiponectin, or a gene encoding the domain or adiponectin. According to the present invention, there is provided a preventive or therapeutic agent capable of directly preventing intimal thickening, which constitutes an essential feature of arteriosclerosis. This effect can be attained through arresting the onset and development of arteriosclerosis by reducing the expression level of scavenger receptor A in arterial walls and preventing lipid buildup in macrophages.

The present invention relates to genetically edited swine which produce CD163 protein in which the scavenger receptor cysteine-rich 5 (SRCR5) domain (also known as CD163 domain 5) has been deleted. Such swine have been found to be healthy and do not exhibit negative properties, and are resistant to PRRSV infection. CD163 expressed in the edited swine also demonstrates retention of the ability to function as a haemoglobin-haptoglobin scavenger. Methods of producing such swine are also provided.

The invention belongs to the field of biological engineering, and in particular to recombinant expression and purification of a fifth functional domain of an oxLDL binding protein human serum beta 2-glycoprotein I and the application thereof to diagnosis prevention and treatment of atherosclerosis. A designed primers pair is subjected to PCR amplification on a T vector of a beta 2-GPI gene fragment to obtain a gene fragment of a beta 2-GPI fifth functional domain; and pPICZ alpha A-DV is constructed by cloning, and is then subjected to power transformation to obtain a positive strain, which is subjected to recombination and purification to obtain a P.r beta 2-GPI-DV protein. The possibility of using the recombinant protein as a drug in the prevention and treatment of atherosclerosis and the feasibility of detecting the oxLDL content in serum are proved. The P.r beta 2-GPI-DV recombinant protein has purity above 90%, can reduce the content of oxLDL / beta 2-GPI binary compound in the serum, and then inhibit the uptake of oxLDL by scavenger receptors on the surface of macrophage, so as to achieve the effect of preventing and treating atherosclerosis; and because of the combination specificity with oxLDL, the P.r beta2-GPI-DV can realize the specific detection of oxLDL in serum.

The present invention features methods of screening for compounds that inhibit HCV binding to a cell, methods of inhibiting IICV entry into a cell, and methods of actively or prophylactically treating against an IICV infection. The different methods are based on the identification of the scavenger receptor class B type I as a target site for HCV E2 binding to a cell.

According to the invention there is provided a method of treatment or prophylaxis of atherosclerosis, hypercholesterolemia or a cardiovascular disease associated with atherosclerosis, which method comprises administration of one or more Growth Hormone Releasing Peptides (GHRPs) to a patient in need of such treatment or prophylaxis. There are also provided methods of reducing blood plasma cholesterol levels, as well as methods of modulating the expression of the scavenger receptor CD36 and genes involved in cellular cholesterol efflux.

The present invention describes methods and compositions for stimulating the growth, proliferation, differentiation and/or mobilization of stem cells and/or progenitor cells. The method involves administering an effective amount of a substance that activates a CD163 hemoglobin scavenger receptor signaling pathway. The methods and compositions are useful for stimulating hematopoiesis and treating a variety of disorders, including cytopenias, anemia, and for preparing cells for transplantation.

A chimeric protein is made from the combination of (i) a pathogen recognition module derived from a scavenger receptor and (ii) an anchor domain from a different scavenger receptor. The chimeric protein binds to specific pathogens and is useful in various treatments.

The inventors have found that CD6, a member of the Scavenger Receptor Cysteine-Rich (SRSR) superfamily expressed on human lymphocytes binds to Gram-positive and Gram-negative bacteria, as well as to other microbial structures. Thus, a CD6 product is useful for the manufacture of a medicament for therapeutic and/or preventive treatment of an infectious disease or of an inflammatory condition related to an infectious disease or to the presence of a product derived from an infectious agent in a mammal including a human. Examples of such inflammatory conditions are systemic inflammatory response syndrome (SIRS), sepsis, severe sepsis and septic shock.

Novel scavenger receptors having an SR structure and a collectin-like structure are provided, which can be utilized in the elucidation of mechanisms of macrophage and basic immunity; in the elucidation of mechanisms of the development of a wide variety of diseases such as arteriosclerosis, diabetic complications and Alzheimer's disease, hyper β-lipoproteinemia, hypercholesterolemia, hypertriglyceridemia, hypo α-lipoproteinemia, transplantation, atherectomy, post angiogenic restenosis, bacterial infections; in the diagnostic, prophylactic and therapeutic methods thereof; and in the development of reagents and drugs for the same. The novel scavenger receptors include proteins comprising an amino acid sequence set out in SEQ ID NO: 2, 4 or 24 or proteins having equivalent properties to the same, or derivatives or fragments thereof as well as isolated polynucleotides comprising a nucleotide sequence encoding these proteins, and related molecules such as antibodies, antagonists and the like. Also disclosed are methods for the treatment using the same.

The present invention relates to the field of single nucleotide polymorphisms (SNPs) and uses therefore as a predictor of diseases and conditions. Specifically, the present invention provides methods and kits useful in determining whether a subject is at increased risk for developing a cardiovascular disease by screening for the presence of a SNP in the scavenger receptor class B type I (SR-BI) gene of a subject.